Unknown

Dataset Information

0

MicroRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma.


ABSTRACT: Previous studies showed that five miRNAs (miR-885-5p, miR-1274, miR-210-3p, miR-224 and miR-1290) were upregulated the most in clear cell renal cell carcinoma (ccRCC). Our focus was to understand from a clinical standpoint the functional consequences of upregulating miR-210-3p. Towards this, we utilized the CRISPR/Cas9 gene editing system to deplete miR-210-3p in RCC cell lines (786-o, A498 and Caki2) and characterized the outcomes. We observed that miR-210-3p depletion dramatically increased tumorigenesis, including altering the morphology of A498 and Caki2 cells in a manner characteristic of epithelial-mesenchymal transition (EMT). These results were corroborated by in vivo xenograft studies, which showed enhanced growth of tumors from miR-210-3p-depleted A498 cells. We identified Twist-related protein 1 (TWIST1) as a key target of miR-210-3p. Analysis of the ccRCC patient data in The Cancer Genome Atlas database showed a negative correlation between miR-210-3p and TWIST1 expression. High TWIST1 and low miR-210-3p expression associated with poorer overall and disease-free survival as compared to low TWIST1 and high miR-210-3p expression. These findings suggest that renal cell carcinoma progression is promoted by TWIST1 suppression mediated by miR-210-3p.

SUBMITTER: Yoshino H 

PROVIDER: S-EPMC5400553 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma.

Yoshino Hirofumi H   Yonemori Masaya M   Miyamoto Kazutaka K   Tatarano Syuichi S   Kofuji Satoshi S   Nohata Nijiro N   Nakagawa Masayuki M   Enokida Hideki H  

Oncotarget 20170301 13


Previous studies showed that five miRNAs (miR-885-5p, miR-1274, miR-210-3p, miR-224 and miR-1290) were upregulated the most in clear cell renal cell carcinoma (ccRCC). Our focus was to understand from a clinical standpoint the functional consequences of upregulating miR-210-3p. Towards this, we utilized the CRISPR/Cas9 gene editing system to deplete miR-210-3p in RCC cell lines (786-o, A498 and Caki2) and characterized the outcomes. We observed that miR-210-3p depletion dramatically increased tu  ...[more]

Similar Datasets

| S-EPMC10185590 | biostudies-literature
| S-EPMC5714046 | biostudies-literature
| S-EPMC10491828 | biostudies-literature
| S-EPMC6648350 | biostudies-literature
| S-EPMC8840632 | biostudies-literature
| S-EPMC8161468 | biostudies-literature
| S-EPMC10556147 | biostudies-literature
| S-EPMC6004052 | biostudies-literature
| S-EPMC9746033 | biostudies-literature
| S-EPMC8578331 | biostudies-literature